

Document the Path to Wound Healing with MolecuLight *i:X*[™]

Abdominoplasty (“tummy tuck”) is one of the most commonly performed aesthetic procedures and associated with many complications, including infection, at a rate of 3-10%.¹ In this case, a 41-year-old woman experienced dehiscence and surgical site infection after an abdominoplasty, and was referred to a wound care specialist. Red fluorescence, as visualized on the MolecuLight *i:X*, confirmed the presence of bacteria² at the periphery of the wound. To eliminate the bacterial load, the periphery of the wound was vigorously cleaned, and silver-based antimicrobials were applied in conjunction with negative pressure wound therapy. Follow-up care was provided and by Day 3, imaging indicated that the bacterial load was reduced and the size of the wound had decreased. With rapid feedback on surface area reduction and the effectiveness of therapy, a less onerous treatment was planned and indeed the wound achieved a 54.8% reduction in surface area in 4 weeks, indicating a rapidly healing path.



Practitioner

Rose Raizman RN-EC, MSc, with over 19 years of experience, leads the Save Our Skin (SOS) team at Scarborough & Rouge Hospital located in Toronto, Canada, to combat pressure ulcers of hospital inpatients. She also oversees the wound care clinic for inpatients and outpatients.



Patient Condition

41-year-old female patient with an abdominoplasty surgical site infection. Received silver-based antimicrobials in conjunction with negative pressure wound therapy. Once the bacterial load was reduced, the clinician decreased the frequency of dressing changes.

DAY 1




Fig. 1




Fig. 2



Fig. 3

Red fluorescing bacteria visualized by the MolecuLight *i:X* (Fig. 1) prompted a change in treatment plan to reduce the bacterial load. Red fluorescing bacteria decreased after vigorous cleaning (Fig. 2). Wound measurement was captured to document wound size prior to treatment (Fig. 3).

DAY 3




Fig. 4




Fig. 5

Absence of red bacterial fluorescence and decrease in wound size demonstrated treatment effectiveness, and as a result, the clinician reduced the frequency of dressing changes.

WEEK 2




Fig. 6

WEEK 3




Fig. 7

WEEK 4




Fig. 8

Wound measurements taken during follow-up visits confirmed the size of the wound was decreasing steadily. By Week 4, the wound achieved a 54.8% reduction in surface area, indicating a rapidly healing path.

The MolecuLight *i:X*[™] Imaging Device is not available in the US.



MolecuLight
LOOK TO HEAL[®]

MolecuLight *i:X*[™] Wound Intelligence Device

The MolecuLight *i:X* allows clinicians to quickly, safely and easily visualize bacteria³ and measure wounds⁴ at the point of care so they have maximum insights for accurate treatment selection and accelerated healing.³

Testimonial

“The decreased red bacterial fluorescence after vigorous cleaning gave me confidence that the bioburden could be managed with dressing changes that decreased in frequency. Furthermore, using the wound measurement feature it was easy to calculate that the wound size had decreased by over 50% in just 4 weeks, meaning that the treatment was effective and the wound was indeed on a healing trajectory.”

— Rose Raizman RN-EC, MSc

View MolecuLight *i:X*[™] in action.
Visit moleculight.com

+1.647.362.4684
Toll Free 1.877.818.4360 (Canada)
info@moleculight.com

Follow us online: [!\[\]\(3211b5d1d968fc1665909b34f9f16010_img.jpg\)](#) [!\[\]\(d47ad152ec3d86a04ad64c8049e1f17f_img.jpg\)](#) [!\[\]\(6b7fbb0b7bdb78cadf73d50851a4dfb1_img.jpg\)](#)



References:


Images provided by Rose Raizman, RN-EC, MSc, Scarborough & Rouge Hospital, ON, Canada MolecuLight Clinical Case 0066.

1. Winocour J, *et al.* Abdominoplasty: Risk Factors, Complication Rates, and Safety of Combined Procedures. *Plast Reconstr Surg.* 2015 Nov;136(5):597e-606e.
2. Rennie MY, *et al.* *J Wound Care.* 2017 Aug 2;26(8):452-460.
3. DaCosta, R.S. *et al.* Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. *PLoS One.* 2015 Mar 19;10(3).
4. MolecuLight Inc. Case Study 0051 Track Wound Size and Bacterial Presence with the MolecuLight *i:X*. 2016.

©2018 MolecuLight[®] Inc. All Rights Reserved. PN 1377 Rev 1.0

The MolecuLight *i:X*[™] Imaging Device is approved by Health Canada (Medical License #95784) and has CE marking (Certificate #G1160292355002) for sale in Canada and the European Union. The MolecuLight *i:X*[™] Imaging Device is not available in the US.

MolecuLight[®] and Look to Heal[®] are Registered Trademarks in Canada, the US, and the EU.



Bacteria appear red in image